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Abstract
Introduction The aim of the study was to retrospectively define
specific features of the technetium-99m pentavalent
dimercaptosuccinic acid (99mTc-(V)DMSA) and technetium-
99m 2-methoxy isobutyl isonitrile (99mTc-Sestamibi [99mTc-
MIBI]) distribution in ductal breast carcinoma in situ and lobular
breast carcinoma in situ (DCIS/LCIS), in relation to
mammographic, histological and immunohistochemical
parameters.
Materials and methods One hundred and two patients with
suspicious palpation or mammographic findings were submitted
preoperatively to scintimammography (a total of 72 patients with
99mTc-(V)DMSA and a total of 75 patients with 99mTc-Sestamibi,
45 patients receiving both radiotracers). Images were acquired
at 10 min and 60 min, and were evaluated for a pattern of diffuse
radiotracer accumulation. The tumor-to-background ratios were
correlated (T-pair test) with mammographic, histological and
immunohistochemical characteristics.
Results Histology confirmed malignancy in 46/102 patients:
20/46 patients had DCIS/LCIS, with or without coexistent
invasive lesions, and 26/46 patients had isolated invasive
carcinomas. Diffuse 99mTc-(V)DMSA accumulation was noticed
in 18/19 cases and 99mTc-Sestamibi in 6/13 DCIS/LCIS cases.
Epithelial hyperplasia demonstrated a similar accumulation
pattern. The sensitivity, specificity, accuracy, positive predictive
value and negative predictive value for each tracer were
calculated. Solely for 99mTc-(V)DMSA, the tumor-to-background
ratio was significantly higher at 60 min than at 10 min and the
diffuse uptake was significantly associated with suspicious
microcalcifications, with the cell proliferation index ≥ 40% and
with c-erbB-2 ≥ 10%.
Conclusion 99mTc-(V)DMSA showed high sensitivity and 99mTc-
Sestamibi showed high specificity in detecting in situ breast
carcinoma (99mTc-(V)DMSA especially in cases with increased
cell proliferation), and these radiotracers could provide
clinicians with preoperative information not always obtainable by
mammography.
Keywords: ductal carcinoma in situ, extensive intraductal carcinoma, lobular breast carcinoma in situ, scintimammography, 99mTc-(V)DMSA, 99mTc-
Sestamibi
DCIS = ductal carcinoma in situ; EIC = extensive intraductal carcinoma; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; Ki-67 = 
cell proliferation index; LCIS = lobular carcinoma in situ; SD = standard deviation; T/B, tumor-to-background; 99mTc-(V)DMSA = technetium-99m 
pentavalent dimercaptosuccinic acid; 99mTc-Sestamibi (99mTc-MIBI) = technetium-99m 2-methoxy isobutyl isonitrile.Breast Cancer Research    Vol 7 No 1    Papantoniou et al.
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Introduction
Ductal carcinoma in situ (DCIS) of the breast, alone or in
the presence of an invasive tumor (invasive ductal carci-
noma [IDC]), presents a problem in its detection and treat-
ment. DCIS represents a number of biologically different
processes that exhibit variable frequencies of occult inva-
sion and variable risks for local recurrence, after attempts
at excision biopsy or lumpectomy. The term 'extensive intra-
ductal component' or 'extensive intraductal carcinoma'
(EIC) is defined as DCIS within and around an invasive
tumor, comprising at least 25% of the neoplasm. Of all IDC
cases, 15–30% are considered to have EIC [1]. Tumors
that are predominantly DCIS and appear with focal invasion
are also classified as EIC.
DCIS not within the confines of the invasive tumor, but fre-
quently in the adjacent breast tissue, makes breast-con-
serving surgical treatment less safe with regard to the
recurrence rate. The great majority of recurrences are
observed at or near the site of the primary tumor. On path-
ological and radiological evaluation of mastectomy speci-
mens, some studies [1] have shown that EIC tumors
commonly had DCIS not only in their immediate vicinity, but
also as far as 4–6 cm from the invasive tumor. The risk of
local recurrence after a breast-conserving procedure can
be evaluated according to the histological type, the extent
of the lesion and the state of the surgical margins. It has
been reported that the local recurrence rate after a limited
resection of the tumor, followed by radiotherapy, is signifi-
cantly greater for EIC-positive patients than for EIC-nega-
tive patients [2,3]. If the real extent of EIC was known
preoperatively, it might be possible to safely limit the breast
resection, since an initial wide excision would constitute
overtreatment for the majority of patients not having a sub-
stantial amount of DCIS outside the invasive tumor. The
fact that younger patients are more likely than older ones to
have EIC, and that the association between EIC and breast
cancer recurrence is stronger in premenopausal women
than in postmenopausal women, renders the detection of
such lesions imperative [1].
Mammographic evidence of microcalcifications with a cer-
tain form and distribution is presently the only method of
detecting the presence of DCIS. The failure of mammogra-
phy to recognize DCIS or EIC in radiologically dense
breasts in young populations raises a significant problem.
Scintimammography with technetium-99m 2-methoxy iso-
butyl isonitrile (99mTc-Sestamibi [99mTc-MIBI]) has been
used to detect primary breast cancer [4-8]. It concentrates
in cancer cells by an energy-requiring transport mechanism
and a transmembrane electronegative potential, in addition
to nonspecific mechanisms, and it is stored within the mito-
chondria. Only a few reports [9,10] have discussed the effi-
cacy of 99mTc-Sestamibi in detecting DCIS.
Technetium-99m pentavalent dimercaptosuccinic acid
(99mTc-(V)DMSA) is a tumor-seeking agent already known
for its efficacy in detecting medullary thyroid carcinoma. Its
mechanism of accumulation has been thought to be related
to the structural similarity between the (V)DMSA core and
the phosphate anion (PO4 
3-), which is avidly taken up by
some cancer cells [11,12]. Denoyer and colleagues
recently reported that the radiotracer uptake is specifically
mediated by NaPi cotransporter type III in cancer cells, sim-
ilar to phosphate ions, which enter cells via NaPi cotrans-
porters [13], while other reports suggest that its uptake in
tumors is related to glucose metabolism-mediated acidosis
[14]. 99mTc-(V)DMSA has been tried out in identifying inva-
sive and preinvasive breast cancer [15-17].
The present study retrospectively assessed the capability
of  99mTc-(V)DMSA and 99mTc-Sestamibi to image DCIS
and EIC. The study also investigated whether this was
related to the presence of suspicious microcalcifications
on mammography, stromal reaction, lymphocytic infiltration
and immunohistochemical parameters such as the cell pro-
liferation index (Ki-67), c-erbB-2, and p53 expression.
Table 1
Inclusion and exclusion criteria of the study
Inclusion criteria Exclusion criteria
Female sex Pregnancy
Age older than 21 years Recurrent disease
Not pregnant Previous mastectomy
Suspicious lesion of the breast (on palpation or mammography) Fine needle aspiration within 1 week prior to scintimammography
Recommendation for excisional biopsy after mammography Core biopsy during the previous 4 weeks
Informed consent of the patient Previous chemotherapy
Medically unstable patient (severe arrhythmia, heart failure or recent surgery)Available online http://breast-cancer-research.com/content/7/1/R33
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Materials and methods
Patients and scintimammography
A total of 102 women (mean age ± standard deviation
[SD], 62.5 ± 12.49 years) referred with suspicious breast
lesions on physical examination and/or an abnormal mam-
mogram underwent 99mTc-Sestamibi and/or 99mTc-
(V)DMSA scintimammography prior to any surgical inter-
vention. All patients were intended to have studies per-
formed with both agents. The first agent to be used was
selected on a random basis. Not all patients managed to
have the second study performed preoperatively, for vari-
ous reasons. Forty-five patients underwent both 99mTc-
(V)DMSA and 99mTc-Sestamibi breast scintigraphy at sep-
arate sessions, in a head-to-head, double-phase study with
a 48-hour time interval. Twenty-seven patients underwent
only  99mTc-(V)DMSA and 30 patients underwent only
99mTc-Sestamibi scintimammography. A total of 72/102
patients therefore underwent 99mTc-(V)DMSA and a total of
75/102 patients underwent 99mTc-Sestamibi scintigraphy.
Inclusion and exclusion criteria for entry into the study are
summarized in Table 1. The study was in accordance with
the ethical principles of the Declaration of Helsinki.
Early and late planar images (at approximately 10–20 min
and 60–70 min, respectively) were acquired, in the lateral
prone and anterior supine positions, after intravenous
administration of 925–1100 MBq radiotracer. Acquisitions
were obtained using a special positioning pad (PBI-2 Scin-
timammography Pad Set®; Pinestar Technology Inc.,
Greenville, PA, USA).
Scintimammography was performed using a single-head γ
camera (Sophycamera DS7®; Sopha Medical Vision Inter-
national, Buc Cedex, France), equipped with a high-resolu-
tion parallel hole collimator connected to a dedicated
computer (Sophy NxT®; Sopha Medical Vision Interna-
tional). The matrix was 256 × 256 pixels and the photopeak
was centered at 140 keV, with a symmetrical 10% window.
The acquisition time for images with both radiotracers var-
ied between 7 min and 10 min per view (the time required
to acquire 2,000,000–2,500,000 counts per image). Tom-
ographic imaging (single-photon emission computerized
tomography) was not performed since it has not been
found to be superior to planar imaging, regarding the sen-
sitivity and the specificity, for invasive breast tumors [18]
and since no consensus has been reached regarding its
utility. It was considered that no additional information
would be obtained (except for axillary lymph node involve-
ment detection), and tomographic imaging is time consum-
ing and relatively inconvenient for the patient.
99mTc-(V)DMSA was prepared using a domestically availa-
ble kit (DMS(V)/Demoscan®; National Center of Physical
Sciences, Institute of Radioisotopes and Radiodiagnostics
'DEMOKRITOS', Athens, Greece). The kit for the prepara-
tion of 99mTc-Sestamibi (Cardiolite®) was obtained from
Bristol-Myers Squibb GmbH (Regensburg, Germany).
Both pharmaceuticals were labeled with technetium-99m
within the Nuclear Medicine Department.
Diagnosis was made by histopathology of the specimens
obtained surgically. The scintigraphic results and the mam-
mograms were compared with histologic and immunohisto-
chemical findings.
Image analysis
Scintigrams were retrospectively evaluated, regarding the
site, shape, pattern, extent, homogeneity and dispersion of
radiotracer distribution. The background count rate of nor-
mal breast tissue depends on various factors (breast size,
injected radioactivity dose, etc.) and is readily distinguisha-
ble from tracer accumulation in pathological tissue. Any
increased focal radiotracer accumulation was assessed as
suggestive of invasive breast cancer, whereas any other
pattern of more widespread diffuse uptake was assessed
as representing noninvasive lesions [10,15,16]. We set
and evaluated as the criterion for the scintigraphic detec-
tion of noninvasive breast carcinoma the presence of any
pattern of increased radiotracer accumulation other than
focal activity (i.e. diffuse heterogeneous and diffuse homo-
geneous), independently of the coexistence of any focal
increased activity. Accordingly, two experienced nuclear
medicine physicians blinded to any clinical and pathologic
data characterized the scintimammograms as positive or
negative. Disagreement between them was resolved by
consensus or by obtaining a third opinion.
Radiotracer accumulation in breast tumors was evaluated
in early and delayed images (at 10–20 min and 60–70 min
post injection, respectively). This was performed visually
and semiquantitatively. The tumor-to-background (T/B)
ratio was calculated by drawing regions of interest of
standardized size and shape over the site of the greatest
radioactivity within the areas of diffusely increased tracer
uptake – assumed to represent noninvasive in situ lesions
– and over the surrounding normal breast tissue. The same
ratio was calculated for the areas of focal increased tracer
uptake (presumably representing invasive tumor). In the late
(60 min) 99mTc-(V)DMSA images of some cases with exten-
sive DCIS and associated IDC, the margins of the focal
uptake area – corresponding to invasive disease – were
not very clearly demarcated from the diffuse uptake.
Nevertheless, the invasive component was usually clearly
visible on the early (10 min) image. Thus, by comparing
early and late images, that area was avoided when creating
the region of interest for diffuse uptake.
Mammography
All women underwent conventional X-ray mammography
using cranio-caudal and medio-lateral projections. ImagesBreast Cancer Research    Vol 7 No 1    Papantoniou et al.
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were interpreted by two experienced radiologists and were
characterized as positive or negative with regard to the
presence or the absence of suspicious branching and clus-
tered coarse granular-type microcalcifications, suggestive
of in situ carcinoma [19]. Disagreement was resolved by
consensus or by obtaining a third opinion.
Histopathology and immunostaining
The assessment of the extent of the in situ carcinoma was
based on the number of histologic slices containing the
lesion. Whole specimens were examined in serial sections
and the final major diameter of the lesion was estimated by
multiplying the number of slices containing the lesion by
0.3 cm, which is the medium size of a section. The EIC was
defined as DCIS within and around an invasive tumor, com-
prising at least 25% of the neoplasm.
In order to investigate whether any of these factors is asso-
ciated with the diffuse pattern of tracer distribution, an
immunohistochemical method (avidin biotin peroxidase-
horseradish peroxidase complex) was performed on paraf-
fin-embedded breast tissue sections for in situ carcinomas,
for the demonstration of Ki-67, c-erbB-2 and p53 expres-
sion. A semiquantitative estimation of these levels was per-
formed, based on the staining intensity and the percentage
of positive cells. Regarding Ki-67, a threshold of 40–45%
of cells with positive staining is generally used for separat-
ing 'moderate' staining from 'intense' staining. Overexpres-
sion for c-erbB-2 is defined, in cases of invasive carcinoma,
by dense membrane staining in ≥ 10% of the epithelial
cells. Similarly, p53 overexpression is defined by staining in
≥ 10% of the epithelial cell nuclei. Although there is no con-
sensus for defining c-erbB-2 and p53 overexpression in
noninvasive breast carcinoma, the latter generally has the
same pattern as invasive breast carcinoma and thus the
same thresholds could be used [20].
Data analysis
The T-pair test was applied to the T/B ratios of diffuse
lesions between early and late acquisitions. The T/B ratios
in the late (60 min) images for both tracers were also cor-
related with the presence of or the absence of suspicious
mammographic microcalcifications, with the stromal reac-
tion, with lymphocytic infiltration, with Ki-67 values < 40%
and ≥ 40%, with c-erbB-2 values < 10% and ≥ 10%, and
with p53 values < 10% and ≥ 10%, in order to assess any
significant difference in diffuse tracer uptake between
these populations. Finally, linear regression univariate anal-
ysis was performed to reveal any possible correlation
between the T/B ratio at 60 min and the tumor size. For all
tests, P < 0.05 was considered statistically significant.
In vitro assay of 99mTc-(V)DMSA uptake and micro-
autoradiographic study
An  in vivo autoradiographic study performed on tumor
specimens excised immediately after scintimammography
could provide precise data about 99mTc-(V)DMSA localiza-
tion on DCIS areas. Such a study was attempted, but the
radioactivity of the tumor specimen was not sufficient. This
was not surprising, since, according to the literature [21],
in vivo autoradiographic studies in mice require approxi-
mately 37 MBq (1 mCi or 1221 MBq/kg body weight), a
dose that is approximately 66 times higher than the injected
dose per kilogram of body weight in humans. Given the
impossibility of implementing the study as described, the
tumor specimen was thus used for an in vitro autoradio-
graphic study. The frozen tumor tissue of one patient with
DCIS was sliced into serial sections in the cryostat micro-
tome chamber (Microm HM 505 N®; Microm Laborgerate
GmbH, Walldorf, Germany), was mounted onto gelatin-
coated slides, was dried at 37°C for 1 hour and was then
incubated in a solution containing 99mTc-(V)DMSA. The
sections were then exposed to Kodac X-OMATT XAR® film
(Eastman Kodak Co., Rochester, NY, USA) in an autoradi-
ographic cassette for 24 hours.
Results
Breast cancer was histologically confirmed in 46/102
women. Of these women, 26/46 had invasive carcinomas,
mainly ductal (IDC) and lobular (invasive lobular carcinoma
[ILC]). This was found to be the prominent histological
lesion in this group of IDC patients, and these patients
were therefore classified as EIC-negative. The other 20/46
cases were diagnosed as having carcinoma in situ. Of
these, 18/20 presented DCIS: in four cases (patients 9,
12, 17, and 18; see Table 2) DCIS was the sole histologi-
cal finding, while the majority (14 patients) had invasive car-
cinoma (IDC) associated with extensive DCIS clearly
outside the confines of the invasive tumor, and thus these
patients were characterized as EIC-positive. Both the
remaining 2/20 cases had extensive lobular carcinoma in
situ (LCIS), associated with an invasive component (ILC).
EIC was found more frequently in younger women (mean
age ± SD, 57.1 ± 13.7 years for EIC-positive patients ver-
sus 65.8 ± 8.0 years for EIC-negative patients; P < 0.05).
The size of the invasive tumors (IDC/ILC) associated with
extensive DCIS/LCIS ranged from 0.7 to 6.0 cm (mean ±
SD, 2.75 ± 1.50 cm), and the size of in situ carcinomas
ranged from 0.8 to 9.0 cm (mean ± SD, 4.92 ± 1.93 cm).
The basic data of these 20 DCIS/LCIS cases are pre-
sented on an individual basis in Table 2.
Benign breast lesions were found in the remaining 56/102
women. Among them, epithelial hyperplasia (usual type
hyperplasia and/or atypical type hyperplasia) was presentAvailable online http://breast-cancer-research.com/content/7/1/R33
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Table 2
Data of the 20 patients diagnosed with ductal carcinoma in situ/lobular carcinoma in situ (DCIS/LCIS)
Patient Age 
(years)
Histology Grade of 
invasive 
carcinoma 
(IDC/ILC)
Size of 
IDC/ILC 
(cm)
Type of 
DCIS/
LCIS
Size of 
DCIS/
LCIS 
(cm)
Mammogr
aphy with 
suspicious 
microcalcif
ications
Scintimammography Stromal 
reaction
Lymphoc
ytic 
infiltration
p53 
(%)
c-erb B-2 
(%)
Ki-67 
(%)
99mTc-(V) DMSA 99mTc-Sestamibi
Focal 
uptake
Diffuse 
uptake
Focal 
uptake
Diffuse 
uptake
15 0 I D C  +  
DCIS
II 6.0 Comedo 5.0 (+) (+) (+) (+) (+) - - 8 8 50
25 8 I D C  +  
DCIS
III 2.5 Comedo 5.0 (-) (+) (+) (+) (-) - - 0 0 25
34 9 I D C  +  
DCIS
I 1.0 Comedo 6.0 (+) (-) (+) (-) (-) ++ - 0 20 55
46 5 I D C  +  
DCIS
II 5.0 Comedo 9.0 (-) (+) (+) (+) (+) - - 10 50 35
55 4 I D C  +  
DCIS
II 5.0 Comedo 7.0 (+) (+) (+) (+) (+) - - 0 50 45
64 8 I D C  +  
DCIS
II 2.5 Solid 5.0 (-) (+) (+) (-) (-) ++ + 0 0 15
77 7 I D C  +  
DCIS
III 3.0 Comedo + 
cribriform
4.0 (+) (+) (+) (+) (-) + - 0 0 35
84 0 I D C  +  
DCIS
II 1.5/1.8/
2.0 
(multifoc
al)
Comedo 6.0 (+) (+) (+) (+) (-) + - 10 10 10
9 50 DCIS Comedo 0.8 (-) (-) (-) (-) (-) - - 8 15 32
10 53 IDC + 
DCIS
II 1.5 Comedo 4.0 (-) (+) (+) (+) (+) - - 25 0 35
11 86 IDC + 
DCIS
III 2.0 Comedo 3.0 (-) (+) (+) Not 
performed
-- 0 0 4 2
12 66 DCIS - 3.0 (-) (-) (+) Not 
performed
-- 0 0 3 5
13 71 IDC + 
DCIS
II 0.7 Cribriform 8.0 (+) (+) (+) Not 
performed
+++ + 0 80 55
14 60 IDC + 
DCIS
II 2.9 Comedo + 
micropap
illary
5.0 (-) (+) (+) (+) (+) - - 27 75 15
15 50 IDC + 
DCIS
II 2.0 Micropapill
ary
2.0 (-) Not 
performed
(+) (+) - - 0 0 31
16 38 IDC + 
DCIS
III 4.3 Comedo 4.0 (+) (+) (+) Not 
performed
+ ++ 0 50 45
17 61 DCIS Comedo + 
solid
5.0 (+) (-) (+) Not 
performed
- - 20 10 15
18 71 DCIS Comedo + 
solid + 
cribriform
4.5 (+) (-) (+) Not 
performed
- - 13 40 35
19 67 ILC + 
LCIS
II 2.5 6.0 (+) (+) (+) Not 
performed
++ - 0 0 20
20 65 ILC + 
LCIS
III 4.0 6.0 (-) (+) (+) (+) (-) ++ ++ 6 25 38
Patients 1–10, patient 14 and patient 20 belong to the 45 patients of the head-to-head subgroup that underwent both scintigraphic examinations. 
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; 99mTc-(V)DMSA, technetium-99m pentavalent dimercaptosuccinic acid; 99mTc-
Sestamibi (99mTc-MIBI), technetium-99m 2-methoxy isobutyl isonitrile; (+), positive scan or mammogram; (-), negative scan or mammogram; -, 
absent stromal reaction or lymphocytic infiltration; +, mild stromal reaction or lymphocytic infiltration; ++, moderate stromal reaction or lymphocytic 
infiltration; +++, intense stromal reaction or lymphocytic infiltration.Breast Cancer Research    Vol 7 No 1    Papantoniou et al.
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in 14/56 patients, with or without fibrosis, adenosis and
ductal dilatation.
All scintimammograms were characterized as positive or
negative for in situ carcinoma, with reference to the diag-
nostic criteria set for the detection of DCIS/LCIS (i.e. pres-
ence of the pattern of diffusely increased tracer uptake,
regardless of the presence of any focal increased activity).
Any study displaying only focal uptake was therefore a (true
or false) negative for the in situ criterion (Fig. 1). Compara-
tive statistics (sensitivity, specificity, accuracy, positive pre-
dictive value and negative predictive value) for each
radiotracer, in the total patient groups studied with each
one and in the subgroup studied with both (head-to-head
study), are presented in Table 3. The interobserver agree-
ment rate between the two physicians assessing the breast
scans was 92%.
Of the 20/46 breast cancer patients with DCIS/LCIS, 19/
20 underwent 99mTc-(V)DMSA and 13/20 underwent
99mTc-Sestamibi scintimammography (12/20 were part of
the head-to-head subgroup of 45 patients that underwent
both). Locally diffuse, heterogeneous (patchy), poorly cir-
cumscribed increased 99mTc-(V)DMSA accumulation,
sometimes covering and surrounding focal increased
accumulation (if present), was noticed in 16/17 of DCIS
cases (Figs 2,3,4) and in 2/2 LCIS cases (Fig. 5), a total of
18/19 (95%) patients. The one lesion that was not
detected had a size of 0.8 cm (patient 9). A similar pattern
of distribution was found with 99mTc-Sestamibi, but only in
6/13 (46%) patients. Among those 12/20 DCIS/LCIS
patients that underwent both examinations, this pattern of
tracer distribution was noticed in 11/12 patients (92%)
with  99mTc-(V)DMSA and in 5/12 patients (42%) with
99mTc-Sestamibi (Tables 3 and 4).
In women with histologically confirmed usual type hyperpla-
sia and/or atypical type hyperplasia, a similar pattern of
intense diffuse, not patchy, but more homogeneous, 99mTc-
(V)DMSA distribution was observed in 10/14 patients
(71%). Diffuse accumulation of 99mTc-Sestamibi in sites of
Table 3
Statistics for each radiotracer concerning in situ carcinoma detection, in the total group of patients studied and in the subgroup that 
underwent both examinations (double phase study)
99mTc-(V)DMSA radiotracer 99mTc-Sestamibi radiotracer
Head-to-head patients 
(45/102)
Total patients (72/102) Head-to-head patients 
(45/102)
Total patients (75/102)
Sensitivity 92% 95% 42% 46%
Specificity 91% 77% 94% 90%
Accuracy 91% 82% 80% 83%
Positive predictive value 79% 60% 71% 50%
Negative predictive value 97% 98% 82% 89%
99mTc-(V)DMSA, technetium-99m pentavalent dimercaptosuccinic acid; 99mTc-Sestamibi (99mTc-MIBI), technetium-99m 2-methoxy isobutyl 
isonitrile.
Figure 1
A 3-cm infiltrating ductal carcinoma of the right breast A 3-cm infiltrating ductal carcinoma of the right breast. Scintimammog-
raphy, right lateral projection: 99mTc-(V)DMSA at 10 min and 60 min 
(upper row, i-ii); 99mTc-Sestamibi (99mTc-MIBI) at 13 min and 55 min 
(bottom row, iii-iv). Focal radiotracer accumulation (arrowhead) in the 
upper breast hemisphere, corresponding to the invasive tumor, visible 
in early and late images with both radiotracers. There is no diffuse 
uptake pattern in the breast; the studies are considered negative for in 
situ carcinoma.Available online http://breast-cancer-research.com/content/7/1/R33
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epithelial hyperplasia was observed in 6/14 patients
(43%), yet it was less intense in comparison with 99mTc-
(V)DMSA (Fig. 6). In the absence of epithelial hyperplasia,
the benign histological lesions of fibrosis, adenosis and
ductal dilatation alone did not accumulate either of the two
radiotracers. These results are also presented in Table 4.
Figure 2
A 5-cm infiltrating ductal carcinoma, grade 2, with 9-cm, comedo-type,  ductal carcinoma in situ of the right breast (patient 4) A 5-cm infiltrating ductal carcinoma, grade 2, with 9-cm, comedo-type, 
ductal carcinoma in situ of the right breast (patient 4). (a) Mammogra-
phy, medio-lateral projection. Nodule with spiky margins (transparent 
arrow), close to the chest wall in the upper breast hemisphere. (b) 
Scintimammography, right lateral projection: 99mTc-Sestamibi (99mTc-
MIBI) at 5 min and 60 min (upper row, i-ii); 99mTc-(V)DMSA at 10 min 
and 60 min (bottom row, iii-iv). Spindle-shaped focal accumulation 
(arrowhead) in the area corresponding to the radiological abnormality. 
The 60-min 99mTc-(V)DMSA image additionally reveals an extensive 
area of diffuse heterogeneous patchy tracer uptake (arrow) extending 
below and anterior to the margins of the focal accumulation. Lymph 
node involvement in the axilla is visible (curved arrow).
Figure 3
A 6-cm infiltrating ductal carcinoma, grade 2, with coexistent 5-cm duc- tal carcinoma in situ, comedo type, of the left breast (patient 1) A 6-cm infiltrating ductal carcinoma, grade 2, with coexistent 5-cm duc-
tal carcinoma in situ, comedo type, of the left breast (patient 1). (a) 
Mammography, medio-lateral projection. Multinodular opacity with 
abnormal radiating spicules and clustered microcalcifications (transpar-
ent arrow) behind the nipple. (b) Scintimammography, left lateral pro-
jection: 99mTc-Sestamibi (99mTc-MIBI) at 10 min and 65 min (upper row, 
i-ii); 99mTc-(V)DMSA at 15 min and 60 min (bottom row, iii-iv). Increased 
bifocal 99mTc-Sestamibi uptake (arrowheads) behind the nipple, clearly 
defining the invasive component of the tumor. Focal 99mTc-(V)DMSA 
accumulation in the same area (arrowhead), with additional diffuse 
uptake (arrow) extending inferiorly, more prominent at 60 min and corre-
sponding to the in situ tumor component. No diffuse pattern is imaged 
with 99mTc-Sestamibi. (c) Scintimammography, left lateral projection: 
99mTc-(V)DMSA at 60 min (same as (b) iv), with regions of interest 
(ROIs) drawn. ROI selection for diffuse uptake with each tracer is 
based on the comparison between early and late images (see text).
Figure 4
A 4.5-cm ductal carcinoma in situ of the left breast, comedo, solid and  cribriform type (patient 18) A 4.5-cm ductal carcinoma in situ of the left breast, comedo, solid and 
cribriform type (patient 18). (a) Mammography, medio-lateral projection. 
Microcalcifications (transparent arrow) behind the nipple. (b) Scinti-
mammography, left lateral projection: 99mTc-(V)DMSA at 10 min and 60 
min (i-ii). Diffuse semi-lunar accumulation (arrow) extending behind the 
nipple, more prominent in the late image. 99mTc-Sestamibi scan was not 
performed in this patient.
Figure 5
A 4-cm infiltrating lobular carcinoma, grade 3, associated with 6-cm  lobular carcinoma in situ (LCIS) of the left breast in a 65-year-old  woman (patient 20) A 4-cm infiltrating lobular carcinoma, grade 3, associated with 6-cm 
lobular carcinoma in situ (LCIS) of the left breast in a 65-year-old 
woman (patient 20). (a) Mammography, cranio-caudal projection. Nod-
ular opacity (asterisk) in the inner hemisphere of the breast. (b) Scinti-
mammography, left lateral projection: 99mTc-Sestamibi (99mTc-MIBI) at 
10 min and 60 min (upper row, i-ii); 99mTc-(V)DMSA at 10 min and 60 
min (bottom row, iii-iv). Focal increased uptake (arrowhead) between 
upper and lower breast hemisphere, imaged by both radiotracers, cor-
responding to an invasive tumor. A diffuse patchy 'V'-shaped tracer 
accumulation (arrows), surrounding the focal activity and extending 
anterior to it, is revealed with 99mTc-(V)DMSA at 60 min only (iv). It cor-
responds to LCIS.Breast Cancer Research    Vol 7 No 1    Papantoniou et al.
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In the series studied, the T/B ratio for 99mTc-(V)DMSA
uptake in the sites of diffuse accumulation pattern
demonstrated a tendency to increase over time (Figs
2,3,4,5,6). Semiquantitative analysis (T/B ratio) performed
separately in DCIS and in IDC revealed a statistically signif-
icant increase in late images only of the diffuse 99mTc-
(V)DMSA accumulation in DCIS (mean ± SD, 1.27 ± 0.22
at 10 min versus 1.76 ± 0.25 at 60 min; P < 0.01). On the
contrary, T/B ratios for the focal 99mTc-(V)DMSA uptake in
invasive tumors were not significantly increased in the late
acquisitions (mean ± SD, 1.76 ± 0.28 at 10 min versus
1.94 ± 0.28 at 60 min; P > 0.05). The pattern of diffuse
99mTc-(V)DMSA distribution observed in epithelial hyper-
plasia demonstrated a similar tendency to increase over
time. The T/B ratios for 99mTc-Sestamibi did not demon-
strate significant variability with time, either in DCIS or in
IDC (mean ± SD for DCIS, 1.34 ± 0.29 at 10 min versus
1.33 ± 0.33 at 60 min; P > 0.05; and mean ± SD for IDC,
2.06 ± 0.97 at 10 min versus 1.98 ± 0.84 at 60 min; P >
0.05). Similarly, the diffuse 99mTc-Sestamibi distribution
observed in epithelial hyperplasia did not appear to
increase significantly over time. Patients with LCIS and
associated ILC gave parallel results, but due to the limited
number of cases (n = 2) they could not be statistically
evaluated.
Linear regression univariate analysis revealed no statisti-
cally significant correlation between the 99mTc-(V)DMSA T/
B ratio at 60 min and tumor size (r = 0.28, P > 0.1).
Mammography depicted suspicious microcalcifications in
10/20 (50%) patients with DCIS/LCIS (Table 2). The dif-
fuse uptake of 99mTc-(V)DMSA in DCIS/LCIS at 60 min
was significantly higher in patients with suspicious micro-
calcifications on mammography as compared with patients
without (mean ± SD T/B ratio, 1.81 ± 0.05 versus 1.4 ±
0.07, respectively; P  = 0.003). 99mTc-Sestamibi diffuse
uptake at 60 min was not significantly different between the
patient groups with and without microcalcifications (mean
± SD T/B ratio, 1.49 ± 0.19 versus 1.31 ± 0.09, respec-
tively; P = 0.49).
An intense stromal reaction was found in 1/20 patient, a
moderate stromal reaction in 4/20 patients, and a mild
stromal reaction in 3/20 patients with DCIS/LCIS; a total of
Table 4
Scintigraphic identification of breast carcinoma in situ with 99mTc-(V)DMSA and 99mTc-Sestamibi: classification of the studied 
population (n = 102) according to the histological diagnosis and the scintimammographic criterion set for ductal carcinoma in situ/
lobular carcinoma in situ (DCIS/LCIS)
Malignant lesions (n = 46) Benign lesions (n = 56)
Histology Carcinoma in situ, alone, or with 
invasive component (DCIS/LCIS ± 
IDC/ILC) 
(n = 20)
Invasive carcinoma (IDC/ILC)
(n = 26)
Lesions with usual type, or atypical 
hyperplasia (UTH/ATH) 
(n = 14)
Lesions without hyperplasia (fibrosis, 
adenosis and ductal dilatation) 
(n = 42)
Radiotracer 99mTc-(V)DMSA 
(n = 19)
99mTc-Sestamibi 
(n = 13)
99mTc-(V)DMSA 
(n = 25)
99mTc-Sestamibi 
(n = 20)
99mTc-(V)DMSA
(n = 14)
99mTc-Sestamibi 
(n = 14)
99mTc-(V)DMSA
(n = 14)
99mTc-Sestamibi 
(n = 28)
Results
(-)
(n = 28)
(+) 
(n = 18)
(-) 
(n = 1)
(+) 
(n = 6)
(-) 
(n = 7)
(+) 
(n = 2)
(-) 
(n = 23)
(+)
(n = 0)
(-) 
(n = 20)
(+) 
(n = 10)
(-) 
(n = 4)
(+) 
(n = 6)
(-) 
(n = 8)
(+) 
(n = 0)
(-) 
(n = 14)
(+) 
(n = 0)
Classification TP FN TP FN FP TN FP TN FP TN FP TN FP TN FP TN
99mTc-(V)DMSA, technetium-99m pentavalent dimercaptosuccinic acid; 99mTc-Sestamibi (99mTc-MIBI), technetium-99m 2-methoxy isobutyl 
isonitrile; EIC, extensive intraductal component; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; UTH, usual type hyperplasia; ATH, 
atypical type hyperplasia; (+), positive scan; (-), negative scan; TP, true positive; FN, false negative; FP, false positive; TN, true negative.
Figure 6
Atypical epithelial hyperplasia of the right breast in a 41-year-old  woman Atypical epithelial hyperplasia of the right breast in a 41-year-old 
woman. Scintimammography, right lateral projection: 99mTc-(V)DMSA 
at 15 min and 75 min (upper row, i-ii); 99mTc-Sestamibi (99mTc-MIBI) at 
10 min and 70 min (bottom row, iii-iv). Increased diffuse homogeneous 
99mTc-(V)DMSA uptake (arrow) at early and late acquisitions, more 
prominent in the late image. Very faint (hardly visible) 99mTc-Sestamibi 
activity (arrow) in the same area.Available online http://breast-cancer-research.com/content/7/1/R33
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8/20 patients (40%). Microcalcifications combined with
stromal reaction appeared in 6/20 cases. Mild or moderate
lymphocytic infiltration was noted in 4/20 patients (20%).
Pure comedo was the most prominent type (10/18) among
DCIS (Table 2). No statistically significant difference was
found in 99mTc-(V)DMSA or 99mTc-Sestamibi uptake
between patients with stromal reaction and/or lymphocytic
infiltration and those patients without.
With reference to the studied immunohistochemical param-
eters in DCIS/LCIS patients, the Ki-67 value ranged from
10% to 55% (mean ± SD, 33.4 ± 13.4%), p53 ranged
from 0% to 27% (mean ± SD, 6.4 ± 8.8%) and c-erbB-2
ranged from 0% to 80% (mean ± SD, 21.7 ± 26.4%)
(Table 2).
The uptake of 99mTc-(V)DMSA was significantly higher in
patients with Ki-67 overexpression (≥ 40%) as compared
with patients with Ki-67 levels < 40% (mean ± SD T/B ratio
at 60 min, 1.86 ± 0.027 versus 1.52 ± 0.047, respectively;
P = 0.025]. No significant difference was found in 99mTc-
Sestamibi scans in relation to Ki-67 levels ≥ 40% and <
40% (mean ± SD T/B ratio at 60 min, 1.51 ± 0.27 versus
1.24 ± 0.08, respectively; P = 0.46).
Overexpression of c-erbB-2 (≥ 10%) was associated with
higher 99mTc-(V)DMSA uptake in DCIS/LCIS (mean ± SD
T/B ratio at 60 min, 1.89 ± 0.01 versus 1.52 ± 0.09 for val-
ues ≥ 10% and < 10%, respectively; P = 0.004). 99mTc-
Sestamibi uptake was not significantly different between
women with c-erbB-2 values ≥ 10% and < 10% (mean ±
SD T/B ratio at 60 min, 1.43 ± 0.06 versus 1.3 ± 0.16,
respectively; P = 0.64).
Diffuse uptake of both 99mTc-(V)DMSA and 99mTc-Sesta-
mibi was not significantly different with regard to p53 val-
ues < 10% and ≥ 10% (mean ± SD T/B ratio at 60 min,
1.71 ± 0.068 versus 1.72 ± 0.06, respectively, for 99mTc-
(V)DMSA; P = 0.93; and 1.60 ± 0.11 versus 1.29 ± 0.17,
respectively, for 99mTc-Sestamibi; P = 0.78).
The c-erbB-2 levels were significantly higher in DCIS cases
with coexistent IDC (EIC-positive) than in EIC-negative
patients (P < 0.05), whereas p53 expression did not dem-
onstrate such a statistically significant difference.
In vitro autoradiography of the breast tumor of one patient
with DCIS revealed a very good correlation between the
regional distribution of 99mTc-(V)DMSA radioactivity and
the distribution of DCIS cell clumps, as observed after
hematoxylin & eosin staining of the same sections (Fig. 7).
Discussion
In situ breast carcinoma tumors are very difficult to identify,
and the only available method to date for their detection is
the evaluation of the shape and distribution of microcalcifi-
cations on mammography, with all the limitations inherent in
this method (dense breasts, scars, implants, etc.).
Scintigraphic imaging of EIC, DCIS or epithelial hyperpla-
sia with 99mTc-(V)DMSA has already been reported
[15,16]. Few reports have been published concerning the
ability of 99mTc-Sestamibi not actually to detect DCIS, but
rather to improve invasive breast cancer detection in the
presence of DCIS [9,10], and these studies seem to be
contradictory. Howarth and colleagues [10] reported no
change in sensitivity in the presence or absence of carci-
noma in situ, and furthermore that there is no relationship
between 99mTc-Sestamibi uptake and DCIS, except in the
presence of an invasive tumor. Several other authors, how-
ever, have suggested that diffuse 99mTc-Sestamibi uptake
in benign breast disorders was associated with proliferative
changes [15,22,23], demonstrating an increased risk of
developing into breast cancer, while other workers
described hormonal influence to be the cause of diffuse
breast uptake on scintimammography [24]. In the present
study, hormonal influence or the menstrual cycle could not
be responsible for this kind of tracer distribution, since all
but two women were postmenopausal and they were not
on any hormone replacement therapy.
In the group of patients with breast malignancy, the
detected invasive tumors (IDC/ILC) presented mostly with
focal increased uptake of both radiotracers. On the con-
trary, the pattern of diffuse heterogeneous (patchy) uptake
was mainly observed in cases with DCIS, independently of
the presence of an invasive tumor. Among the 26 invasive
tumors not associated with extensive amounts of in situ
carcinoma, only a couple of cases gave false positive
results (for DCIS) with 99mTc-(V)DMSA (Table 4): one con-
sisted of multiple microscopic foci of IDC, and the other
case presented IDC with intense lymphocytic infiltration.
Figure 7
Ductal carcinoma in situ (DCIS), comedo, solid and cribriform type  (patient 18) Ductal carcinoma in situ (DCIS), comedo, solid and cribriform type 
(patient 18). (a) Tumor section (hematoxylin & eosin, × 25). Regions of 
DCIS (arrowheads), within normal breast tissue (asterisk). (b) In vitro 
99mTc-(V)DMSA autoradiogram of the same section (× 25). Distribution 
of the radioactivity in the same tumor section. The sites of intense tracer 
uptake (curved arrow) appear darker. (c) Overlay of stained tumor sec-
tion and autoradiogram. The histologically detected lesion is well corre-
lated with the tissue sites of intense 99mTc-(V)DMSA uptake.Breast Cancer Research    Vol 7 No 1    Papantoniou et al.
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LCIS was found in two cases, and due to this limited
number specific scintigraphic results could not be statisti-
cally evaluated. They could have been considered as false
positive findings for DCIS, yet their scintigraphic appear-
ance was the same; they both revealed a similar diffuse
inhomogeneous pattern of 99mTc-(V)DMSA uptake, apart
from the focal uptake corresponding to the coexistent ILC.
They could therefore not be separated from DCIS, except
after histological examination of the biopsied tissue, and
thus they are studied together in this series. If this diffuse
uptake was attributable to the lobular invasive component,
known for its peculiar pattern of growth and local invasion,
then it should have been clearly visible from the early (10
min) images, simultaneously with the focal uptake. Yet the
extensive diffuse 99mTc-(V)DMSA uptake was prominent in
the late (60 min) image, whereas the focal tracer uptake
was also visible in the early image (Fig. 4). 99mTc-Sestamibi,
known for its efficacy in imaging invasive carcinoma, in this
case managed to image only the focal uptake in both early
and late images.
The diffuse pattern of radiotracer uptake (not patchy, but
more homogeneous) was also noticed in some cases of
epithelial hyperplasia, more prominently with 99mTc-
(V)DMSA. Epithelial hyperplasia was therefore the major
source of false positive results. The discrimination between
atypical epithelial hyperplasia and in situ carcinoma is
certainly not easy, even on frozen section. Yet any false
positive scan attributable to hyperplasia should not be con-
sidered a major disadvantage, since it may lead to a search
but not to an incorrect final decision concerning excision.
This is because scintigraphic data (in addition to suspi-
cious microcalcifications, if present) can serve as a guide
and provide the surgeon with useful information preopera-
tively, in order to decide the extent of the search and to
facilitate a guided biopsy, rather than directly determine
whether an excision has to be performed.
Increased cell proliferation activity (Ki-67 ≥ 40%) was
found to be significantly correlated with the diffuse 99mTc-
(V)DMSA uptake in breast carcinoma in situ. Papantoniou
and colleagues [25] recently reported this factor to be
independently correlated with focal 99mTc-(V)DMSA
accumulation in invasive breast cancer, while their prelimi-
nary reports [26] revealed that cases of usual type hyper-
plasia imaged with 99mTc-(V)DMSA tend to be related to
elevated Ki-67 values and are therefore at risk of develop-
ing breast malignancy, according to the literature [27-31].
Cutrone and colleagues claimed that increased prolifera-
tive activity is found not only in invasive cancers, but also in
precancerous lesions [27].
Shaaban and colleagues [28], along with several other
reports [29,30], suggested that benign breast lesions such
as epithelial hyperplasia, when associated with increased
levels of Ki-67 and estrogen receptors type A, define a sub-
set of hyperplastic lesions with high risk of subsequent
breast cancer development. Such patients could be
selected for prophylactic antiestrogen therapy to diminish
the proliferative activity [28,31]. The observed tendency of
the 99mTc-(V)DMSA diffuse uptake pattern to increase over
time (being more notable on the delayed 60-min images),
as well as its relation to elevated proliferative cellular activ-
ity (Ki-67), could be considered indicative of the existence
of a distinct primary pathway for the mechanism of its accu-
mulation in tumor tissue. This is considered to reflect the
tracer's uptake in structures that participate in mitotic activ-
ity of cancerous and precancerous cell populations [25].
The possibility for this finding to be due to locally increased
vascularity, angiogenesis or vessel permeability is therefore
highly unlikely; if that was the case, then this diffuse pattern
would have been equally clearly visible in the early 10-min
images.
On the contrary, diffuse 99mTc-Sestamibi distribution was
not found to be significantly correlated with Ki-67 expres-
sion. Palmedo and colleagues [32] reported that the 99mTc-
Sestamibi concentration was one-half that of 99mTc-
(V)DMSA in an experimental model of rats bearing poorly
differentiated breast tumours. Cutrone and colleagues
found a moderate correlation between 99mTc-Sestamibi
uptake and the degree of cellular proliferation [27], while
Cwikla and colleagues did not [33]. Angiogenesis and an
oxidative metabolism seem to be favorable factors for
99mTc-Sestamibi tumor uptake, rather than proliferative
activity [25,29]. This could provide an explanation for the
lower sensitivity of this radiotracer, as compared with
99mTc-(V)DMSA, in imaging such diffuse lesions.
Overexpression of c-erbB-2 (≥ 10%) is found in almost
60% of cases of high-grade comedo-type DCIS, in 10–
40% of IDC and in only a few cases of ILC [34,35]. An
increased c-erbB-2 level was a factor significantly corre-
lated with diffuse 99mTc-(V)DMSA uptake (but not with
99mTc-Sestamibi uptake). This appears reasonable, since
oncoprotein overexpression is usually found in aggressive
in situ carcinomas with increased levels of cell proliferative
activity.
The measurement of Ki-67 and c-erbB-2 on histological
specimens is not related to the size of the tumor. In the
present series, the T/B ratio for 99mTc-(V)DMSA in the late
image was not found to be significantly correlated with
tumor size. It is therefore considered that the correlation
found for the 99mTc-(V)DMSA T/B ratio to Ki-67 and/or c-
erbB-2 expression is independent of tumor size.
p53 overexpression is known to reflect tumor aggressive-
ness and a decreased disease-free interval following ther-
apy. An intriguing finding requiring further investigation,Available online http://breast-cancer-research.com/content/7/1/R33
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however, is that p53 overexpression, unlike that of Ki-67
and c-erbB-2, was not significantly correlated with this pat-
tern of uptake of either tracer in the present series.
DCIS of the comedo type is usually accompanied by a
desmoplastic stromal reaction with pronounced neovascu-
larization. Elastosis is also more common in DCIS [36]. A
variable inflammatory infiltrate is present in the periductal
stroma. This consists of lymphocytes and histiocytes, in
amounts ranging from sparse to abundant [37]. The sug-
gestion that stromal reaction and/or lymphocytic infiltration
could be considered mediators for the diffuse radiotracer
uptake was not confirmed in the studied population.
Suspicious mammographic microcalcifications were
observed in only one-half of the DCIS/LCIS cases, whereas
99mTc-(V)DMSA revealed a diffuse uptake pattern in the
vast majority (18/19 patients). Nevertheless, diffuse uptake
for  99mTc-(V)DMSA (but not for 99mTc-Sestamibi) was
found to be significantly increased in women with suspi-
cious microcalcifications as compared with those without.
A possible explanation for this could be that clustered
microcalcifications are usually found in more aggressive
types of DCIS (such as comedo type), which tend to be
related to increased Ki-67 levels. The majority of DCIS
found in this series were of comedo type. Although it has
been reported for the comedo type that suspicious micro-
calcifications approximately correspond to the histologi-
cally confirmed size, their extent in the present study was
substantially smaller in comparison with the spread of dif-
fuse 99mTc-(V)DMSA uptake, which in turn was found to
correlate very well with the histologically confirmed size of
DCIS. These findings imply that calcium deposits may not
represent a 99mTc-(V)DMSA uptake mechanism, as was
previously presumed [16].
Examining scintimammograms in combination with mam-
mography could help limit false positive results. In the pres-
ence of suspicious microcalcifications, a diffuse 99mTc-
(V)DMSA uptake could be considered more suggestive of
in situ carcinoma. In the absence of microcalcifications,
however, a diffuse 99mTc-(V)DMSA uptake could imply the
possibility of a false positive study, probably due to epithe-
lial hyperplasia.
In vitro 99mTc-(V)DMSA autoradiography of one tumor
specimen demonstrated a very good correlation between
radioactivity uptake and the distribution of foci of DCIS
cells. This is considered a strong indication for the tracer
localization in these cell clumps. Autoradiography
nevertheless needs to be performed in a larger series of
tumor specimens to verify the findings.
Conclusion
99mTc-(V)DMSA displayed an excellent sensitivity and neg-
ative predictive value in detecting DCIS/LCIS, especially in
cases associated with increased cell proliferation (Ki-67)
and c-erbB-2 overexpression, independent of the presence
of suspicious microcalcifications. Its relatively lower
specificity and positive predictive value, caused by false
positive scans mainly attributable to epithelial hyperplasia,
should not be considered a major disadvantage, since to
date there is no diagnostic technique other than suspicious
mammographic microcalcifications to define high-risk
breast areas that should be biopsied. 99mTc-Sestamibi
appeared to be less sensitive, yet it demonstrated a very
good specificity and could also be useful in preinvasive
lesion imaging.
In our opinion, any diffuse tracer accumulation, either as an
isolated finding or extending beyond the margins of a focal,
well-circumscribed accumulation, could be considered to
probably correspond with highly proliferating tissue and to
possibly represent DCIS/LCIS or epithelial hyperplasia.
Since the difference between in situ carcinoma and atypi-
cal type hyperplasia cannot always be discriminated, even
histologically, we note the potential usefulness of scinti-
mammography in imaging these lesions and making them
accessible to biopsy. There is, however, a need for a larger
series of patients to verify these preliminary observations,
as well as prospective studies to estimate its reliability in
affecting treatment decisions.
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